Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Blood Cancer Talks

Episode 22. Management of Low-Risk MDS

20 May 2023

Description

In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA". Here are the key studies discussed:1. ASH choosing wisely: https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely 2. International Consensus Classification (ICC): https://pubmed.ncbi.nlm.nih.gov/35767897/ 3. WHO classification 2022: https://pubmed.ncbi.nlm.nih.gov/35732829/ 4. IPSS-M: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200008 5. Romiplostim in MDS: https://pubmed.ncbi.nlm.nih.gov/29396092/ 6. Low-dose decitabine vs. low-dose azacItidine in lower-risk MDS: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200034 7. Luspatercept in MDS: https://www.nejm.org/doi/full/10.1056/nejmoa1908892 8. Lenalidomide in MDS: https://ascopubs.org/doi/10.1200/JCO.2015.66.0118https://pubmed.ncbi.nlm.nih.gov/21753188/ 9.Iron chelation therapy in MDS: https://pubmed.ncbi.nlm.nih.gov/32203980/ 

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.